As home to companies such as Allergan (NYSE: AGN), Perrigo (NasdaqGS: PRGO) and Mylan (NYSE: MYL), among others, PJP is awash in specialty pharmaceuticals buyers and sellers. For the moment, PJP’s lineup is probably littered more with buyers than sellers, the result of the ETF’s weights to the largest biotech stocks and the aforementioned blue-chip pharma names. However, several of PJP’s other holdings have been bandied about as potential targets.
“The ETF’s 3 percent stake in $112.5 billion Allergan, for example, contributed 16 percent of overall return. A 2.3 percent holding in Salix Pharmaceuticals, meanwhile, which had about a $7 billion market cap when it was acquired, contributed 19.2 percent to overall return,” according to Bloomberg.
PowerShares Dynamic Pharmaceuticals Portfolio
